deuterated apremilast (CTP-730) / BMS, Sun Pharma - LARVOL DELTA

Efficacy and Safety of Apremilast Over 52 Weeks in Patients With Psoriasis in Special Areas and Impaired Quality of Life: Results From EMBRACE (SGDV 2022) - "APR significantly improved QoL and disease severity vs PBO at Week 16 in patients with plaque psoriasis in ≥1 special area, limited skin involvement, and impaired QoL; improvements were maintained through Week 52, At Week 32, QoL responses were similar regardless of whether patients had started APR treatment at Week 0 or Week 16, Adverse events were consistent with the known safety profile of APR, with no new safety signals."

Psoriasis